December 26th 2024, 2:00pm
The treatment combination was found to reduce the risk of follicular lymphoma progression or death by 57%, a study has shown.
December 25th 2024, 7:00pm
Monjuvi plus Revlimid and Rituxan demonstrated improved progression-free survival for patients with relapsed or refractory follicular lymphoma.
December 24th 2024, 4:00pm
CURE® highlights some top stories from the ASH Annual Meeting, focusing on B-cell acute lymphoblastic leukemia, multiple myeloma and other blood cancers.
December 24th 2024, 2:00pm
The real-world effectiveness of Monjuvi for relapsed or refractory diffuse large B-cell lymphoma in the U.S. was demonstrated, according to data from a retrospective analysis.
December 23rd 2024, 2:00pm
Among patients with heavily pretreated chronic lymphocytic leukemia, treatment with Epkinly monotherapy showed deep responses.
December 21st 2024, 3:00pm
Patients newly diagnosed with multiple myeloma who are transplant ineligible or deferred may benefit from receiving a Darzalex treatment combination.
December 19th 2024, 2:00pm
CURE® spoke with an expert about follicular lymphoma, a disease that is still considered incurable.
December 18th 2024, 2:00pm
A combination of Imbruvica and venetoclax showed significantly prolonged progression-free survival in patients with untreated CLL, an expert explained.
December 17th 2024, 4:00pm
Black patients may be more affected by certain side effects from Talvey compared with White patients with multiple myeloma, an expert told CURE®.
December 16th 2024, 4:00pm
Outpatient lymphodepletion followed by Tecartus was found to be safe and effective in treating B-cell acute lymphoblastic leukemia and mantle cell lymphoma.
Aspiring to Make a Difference for Immigrants
Raising Awareness for Adolescents and Young Adults with Cancer
Clinical Trials Enhance Care for Advanced Gastrointestinal Cancers
My 11-Year Metastatic Breast Cancer Story Defied the Standard Path